Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing urologists and radiation oncologists ongoing access to the perspectives and opinions of national and international prostate cancer research leaders.
All content for Prostate Cancer Update is the property of Dr. Neil Love and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing urologists and radiation oncologists ongoing access to the perspectives and opinions of national and international prostate cancer research leaders.
Dr Matthew R Smith from the Massachusetts General Hospital Cancer Center in Boston summarizes recent developments presented at ASCO 2024 for prostate cancer.
Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma.
Dr Petros Grivas from the Fred Hutchinson Cancer Center in Seattle, Washington, discusses the current management of advanced urothelial bladder cancer.
Dr Matthew Galsky from The Tisch Cancer Institute in New York and Dr Ashish Kamat from The University of Texas MD Anderson Cancer Center in Houston summarize recent clinical advances in the management of urothelial bladder cancer, including data from the 2024 AUA annual meeting.
Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field.
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing urologists and radiation oncologists ongoing access to the perspectives and opinions of national and international prostate cancer research leaders.
